Last reviewed · How we verify

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

GeoVax, Inc. · Phase 2 active Biologic Quality 0/100

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 is a Biologic drug developed by GeoVax, Inc.. It is currently in Phase 2 development. Also known as: COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1.

At a glance

Generic nameSynthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Also known asCOH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1
SponsorGeoVax, Inc.
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1

What is Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1?

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 is a Biologic drug developed by GeoVax, Inc..

Who makes Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1?

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 is developed by GeoVax, Inc. (see full GeoVax, Inc. pipeline at /company/geovax-inc).

Is Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 also known as anything else?

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 is also known as COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1.

What development phase is Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 in?

Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 is in Phase 2.

Related